As per our analysis, Tumor Ablation Market in North America will grow at a CAGR of 11.2% from 2019 to 2024.
Tumors are the group of abnormal cells that accumulate together and form lumps. Tumor ablation is a minimally invasive procedure used to destroy cancer cells in the chest, lung, and liver.
Rising Prevalence of cancer is proportional to the growth of the tumor ablation market. As per data published by the American Cancer Society, the incidence of cancer in the United States is 300.2 per 100,000 annually. Similarly in Canada, the number is somewhere around 236.6 cases.
North America Tumor ablation market is driven by key factors such as the growing geriatric population, the increasing number of people affected with cancer, technological advancements in the field of ablation. Increasing demand for minimally invasive cancer treatment procedures and favorable reimbursement structures coupled with rising disposable income are some of the other major factors fuelling the growth of the market.
However, challenges related to ablation procedures and stringent regulatory guidelines delaying product launches are restraining the market growth.
This research report segmented and sub-segmented into the following categories:
Regionally, North America is the largest market for tumor ablation with over 33% share owing to its advanced healthcare infrastructure. Within North America, the United States is the largest market due to favorable reimbursement policies and high government support while Canada is estimated to be the fastest-growing region due to the increasing incidence of cancer.
Key market participants in the North American Tumor Ablation Market profiled in this report are Medtronic Plc., Boston Scientific Corporation, Angiodynamics, Mermaid Medical, HealthTronics, Galil Medical Inc., EDAP TMS S.A., SonaCare Medical, Misonix, Inc. and Neuwave Medical, Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Technology
5.1.1 Radiofrequency Ablation Devices
5.1.2 Microwave Ablation Devices
5.1.3 Cryoablation Devices
5.1.4 Other Ablation Devices
5.2 By Treatment
5.2.1 Surgical Ablation
5.2.2 Laparoscopic Ablation
5.2.3 Percutaneous Ablation
5.3 By Application
5.3.1 Liver Cancer
5.3.2 Breast Cancer
5.3.3 Lung Cancer
5.3.4 Prostrate Metastasis
5.3.5 Other Cancers
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Medtronic Plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Angiodynamics
8.3 Mermaid Medical
8.4 HealthTronics
8.5 Galil Medical Inc.
8.6 EDAP TMS S.A.
8.7 Boston Scientific Corporation
8.8 SonaCare Medical
8.9 Misonix, Inc.
8.10 Neuwave Medical, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
